AWAkira Watanabe

Akira Watanabe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Akira Watanabe has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Shinya Yamanaka

    Affiliations Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan, Gladstone Institute of Cardiovascular Disease, San Francisco, California, United States of America, Department of Anatomy, University of California, San Francisco, San Francisco, California, United States of America

    2 shared publications
  • Akira Katakura

    Department of Oral Pathobiological Science and Surgery, Tokyo Dental College, 2-9-18 Kandamisaki-cho, Chiyoda-ku, Tokyo 101-0061, Japan

    1 shared publication
  • Akira Ohta

    Department of Fundamental Cell Technology, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan

    1 shared publication
  • Akira Tamaoka

    Department of Neurology, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan

    1 shared publication
  • Akito Tanaka

    Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan

    1 shared publication
  • Akitsu Hotta

    Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan

    1 shared publication

Latest Publications

  • Human iPSC–derived nephron progenitor cells treat acute kidney injury and chronic kidney disease in mouse models

    by Toshikazu Araoka, Kosuke Toyohara, Makoto Ryosaka, Chihiro Inui, Maasa Matsuura, Chen Ma, Jun Watahiki, Zhongwei Li, Mio Iwasaki, Akira Watanabe, et al.

    The number of patients requiring dialysis therapy continues to increase worldwide because of the lack of effective treatments for chronic kidney disease (CKD). Furthermore, no curative treatments for acute kidney injury (AKI) have been established. The therapeutic effects of human induced pluripotent stem cell–derived nephron progenitor cells (hiPSC-NPCs) on AKI have been reported in mice but not clinically confirmed. There are also no reports examining the therapeutic potential of hiPSC-NPCs on CKD. Although large numbers of uniform hiPSC-NPCs are required for cell therapies for AKI and CKD, effective expansion cultures remain to be developed. Here, we established a culture medium for cells that enabled more than 100-fold proliferation of hiPSC-NPCs from multiple hiPSC lines in two passages. We demonstrated that hiPSC-NPCs expanded by our medium named CFY or by their conditioned medium alone attenuated kidney injury and improved survival in cisplatin-induced AKI mice. We also observed that hiPSC-NPCs prevented kidney functional decline, interstitial fibrosis, and senescence in aristolochic acid–induced CKD mice. In addition, we found c-MET to be a specific cell surface marker for hiPSC-NPCs and confirmed that purified c-MET + hiPSC-NPCs had therapeutic effects on AKI and CKD mice. Furthermore, we found that hiPSC-NPCs exerted their therapeutic effects in AKI and CKD mice by secreting vascular endothelial growth factor A. Expanded hiPSC-NPCs may be useful cell therapies for AKI and CKD and may open avenues for treating kidney diseases.


  • Open Access

    The pluripotent stem cell-specific transcript ESRG is dispensable for human pluripotency

    by Kazutoshi Takahashi, Michiko Nakamura, Chikako Okubo, Zane Kliesmete, Mari Ohnuki, Megumi Narita, Akira Watanabe, Mai Ueda, Yasuhiro Takashima, Ines Hellmann, et al.

    Human pluripotent stem cells (PSCs) express human endogenous retrovirus type-H (HERV-H), which exists as more than a thousand copies on the human genome and frequently produces chimeric transcripts as long-non-coding RNAs (lncRNAs) fused with downstream neighbor genes. Previous studies showed that HERV-H expression is required for the maintenance of PSC identity, and aberrant HERV-H expression attenuates neural differentiation potentials, however, little is known about the actual of function of HERV-H. In this study, we focused on ESRG, which is known as a PSC-related HERV-H-driven lncRNA. The global transcriptome data of various tissues and cell lines and quantitative expression analysis of PSCs showed that ESRG expression is much higher than other HERV-Hs and tightly silenced after differentiation. However, the loss of function by the complete excision of the entire ESRG gene body using a CRISPR/Cas9 platform revealed that ESRG is dispensable for the maintenance of the primed and naïve pluripotent states. The loss of ESRG hardly affected the global gene expression of PSCs or the differentiation potential toward trilineage. Differentiated cells derived from ESRG-deficient PSCs retained the potential to be reprogrammed into induced PSCs (iPSCs) by the forced expression of OCT3/4, SOX2, and KLF4. In conclusion, ESRG is dispensable for the maintenance and recapturing of human pluripotency.


  • Open Access

    上下顎無歯顎となった骨格性下顎前突症患者に対して上下顎移動術を施行した1例

    by Takeo Shibui, Yusuke Aoki, Miki Watanabe, Masae Yamamoto, Akira Watanabe, Masato Narita, Akira Katakura

    In Japan, the aging rate exceeds 25% and a super-aging society has developed; the situation is expected to continue in the future. Not only adolescents but also middle-aged and/or elderly patients undergoing orthognathic surgery are gradually increasing. There are reports on orthognathic surgery for jaw deformity patients with multiple teeth defects, but no reports on two-jaw surgery in maxillomandibular edentulous patients in Japan. Although the present maxillomandibular edentulous patient was in their 30s, two-jaw surgery was performed to acquire stable occlusion, enable the use of stable dentures, and improve esthetics. A denture fitting the current alveolar ridge was created for surgical planning, then a duplicate denture in which the crown of the denture had been replaced with a contrast-enhanced resin was used. The patient wore the denture and an X-ray photograph was taken. This method made it possible to plan the amount of movement and intermaxillary fixation during surgery. In addition, the patient had a risk of dialysis, but there were no problems during the perioperative period. The patient was postoperatively very satisfied with the treatment outcome. It is thought that the number of maxillomandibular edentulous cases in whom orthognathic surgery is applied will increase in the future.

  • The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis

    by Keiko Imamura, Yuishin Izumi, Akira Watanabe, Kayoko Tsukita, Knut Woltjen, Takuya Yamamoto, Akitsu Hotta, Takayuki Kondo, Shiho Kitaoka, Akira Ohta, et al.

    Amyotrophic lateral sclerosis (ALS), a fatal disease causing progressive loss of motor neurons, still has no effective treatment. We developed a phenotypic screen to repurpose existing drugs using ALS motor neuron survival as readout. Motor neurons were generated from induced pluripotent stem cells (iPSCs) derived from an ALS patient with a mutation in superoxide dismutase 1 (SOD1). Results of the screen showed that more than half of the hits targeted the Src/c-Abl signaling pathway. Src/c-Abl inhibitors increased survival of ALS iPSC-derived motor neurons in vitro. Knockdown of Src or c-Abl with small interfering RNAs (siRNAs) also rescued ALS motor neuron degeneration. One of the hits, bosutinib, boosted autophagy, reduced the amount of misfolded mutant SOD1 protein, and attenuated altered expression of mitochondrial genes. Bosutinib also increased survival in vitro of ALS iPSC-derived motor neurons from patients with sporadic ALS or other forms of familial ALS caused by mutations in TAR DNA binding protein (TDP-43) or repeat expansions in C9orf72. Furthermore, bosutinib treatment modestly extended survival of a mouse model of ALS with an SOD1 mutation, suggesting that Src/c-Abl may be a potentially useful target for developing new drugs to treat ALS.